Protalix BioTherapeutics Issues 2025 Letter to Stockholders - Placera
Protalix BioTherapeutics shares 2024 milestones, including EMA validation for less frequent dosing of pegunigalsidase alfa for Fabry disease, phase I trial results for PRX-115, and repayment of convertible notes. The company looks forward to advancing PRX-115 into phase II in 2025 and continuing growth in sales.
Highlighted Terms
NETs-related diseasesChiesi Farmaceutici S.p.A.Elfabrio®PRX–115PRX–119PRX 115European Medicine AgencyFabry diseaseProtalix BioTherapeuticsU.S. Securities and Exchange Commissionuncontrolled goutAmerican College of RheumatologyPfizer Inc.Chiesi Global Rare Diseasespegunigalsidase alfaElelyso®Uplyso®Brazilian Ministry of HealthFundação Oswaldo Cruz
Related News
Protalix BioTherapeutics Issues 2025 Letter to Stockholders - Placera
Protalix BioTherapeutics shares 2024 milestones, including EMA validation for less frequent dosing of pegunigalsidase alfa for Fabry disease, phase I trial results for PRX-115, and repayment of convertible notes. The company looks forward to advancing PRX-115 into phase II in 2025 and continuing growth in sales.